Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Hepatitis

Hepatitis E vaccination—is HEV 239 the breakthrough?

No approved vaccine is currently available against hepatitis E virus (HEV), which can cause acute hepatitis E. A large-scale phase III study involving more than 100,000 Chinese adults has reported that the recombinant HEV vaccine, HEV 239, prevented acute hepatitis E with a vaccine efficacy of 94–100%.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Purcell, R. H. & Emerson, S. U. Hepatitis E: an emerging awareness of an old disease. J. Hepatol. 48, 494–503 (2008).

    Article  CAS  PubMed  Google Scholar 

  2. Navaneethan, U., Al Mohajer, M. & Shata, M. T. Hepatitis E and pregnancy: understanding the pathogenesis. Liver Int. 28, 1190–1199 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Radha Krishna, Y. et al. Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. Liver Int. 29, 392–398 (2009).

    Article  PubMed  Google Scholar 

  4. Pischke, S. & Wedemeyer, H. Chronic hepatitis E in liver transplant recipients: a significant clinical problem? Minerva Gastroenterol. Dietol. 56, 121–128 (2010).

    CAS  PubMed  Google Scholar 

  5. Pischke, S. et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl. 16, 74–82 (2010).

    Article  PubMed  Google Scholar 

  6. Zhu, F. C. et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 376, 895–902 (2010).

    Article  CAS  PubMed  Google Scholar 

  7. Shrestha, M. P. et al. Safety and efficacy of a recombinant hepatitis E vaccine. N. Engl. J. Med. 356, 895–903 (2007).

    Article  CAS  PubMed  Google Scholar 

  8. Zhang, J. et al. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine 27, 1869–1874 (2009).

    Article  CAS  PubMed  Google Scholar 

  9. Pischke, S. et al. Should all patients with autoimmune hepatitis be screened for HEV-infection [abstract]? J. Hepatol. 52 (Suppl. 1), S135 (2010).

    Article  Google Scholar 

  10. Kamar, N. et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis E virus infection. Gastroenterology 139, 1612–1618 (2010).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant from the German Federal Ministry of Education and Research (01EO0802).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Heiner Wedemeyer.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wedemeyer, H., Pischke, S. Hepatitis E vaccination—is HEV 239 the breakthrough?. Nat Rev Gastroenterol Hepatol 8, 8–10 (2011). https://doi.org/10.1038/nrgastro.2010.207

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2010.207

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing